HILS Key Statistics, Chart & Performance
The current stock price of HILS is 0.2305 USD. In the past month the price decreased by -4.75%. In the past year, price decreased by -70.5%.
HILS Technical Analysis
HILS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HILS. While HILS seems to be doing ok healthwise, there are quite some concerns on its profitability.
HILS Financial Highlights
Over the last trailing twelve months HILS reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS decreased by -160.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
HILS Forecast & Estimates
6 analysts have analysed HILS and the average price target is 4.08 USD. This implies a price increase of 1670.07% is expected in the next year compared to the current price of 0.2305.
HILS Ownership
HILS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.31 | 394.886B | ||
| AMGN | AMGEN INC | 16.65 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.17 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.73 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.31 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 12.92 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.63 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HILS
Company Profile
Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. The company is headquartered in Bridgewater, New Jersey and currently employs 1 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The drug HSB-1216 was found to reduce tumor in burden treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas. The firm uses Quatramer, a tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (TME). Its Trident Artificial Intelligence, an artificial intelligence precision medicine platform used to identify biomarkers in clinical programs to target specific patient segments. The Company’s pipeline includes HSB-1216, HSB-888, HSB-510 and HSB-114. HSB-1216 pipeline is a novel inducer of iron-mediated cell death.
Company Info
HILLSTREAM BIOPHARMA INC
1200 Route 22 East, Suite 2000
Bridgewater NEW JERSEY US
Employees: 1
Phone: 19089553140.0
HILLSTREAM BIOPHARMA INC / HILS FAQ
What does HILLSTREAM BIOPHARMA INC do?
Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. The company is headquartered in Bridgewater, New Jersey and currently employs 1 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The drug HSB-1216 was found to reduce tumor in burden treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas. The firm uses Quatramer, a tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (TME). Its Trident Artificial Intelligence, an artificial intelligence precision medicine platform used to identify biomarkers in clinical programs to target specific patient segments. The Company’s pipeline includes HSB-1216, HSB-888, HSB-510 and HSB-114. HSB-1216 pipeline is a novel inducer of iron-mediated cell death.
Can you provide the latest stock price for HILLSTREAM BIOPHARMA INC?
The current stock price of HILS is 0.2305 USD. The price increased by 2.76% in the last trading session.
Does HILS stock pay dividends?
HILS does not pay a dividend.
What is the ChartMill rating of HILLSTREAM BIOPHARMA INC stock?
HILS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for HILLSTREAM BIOPHARMA INC?
HILLSTREAM BIOPHARMA INC (HILS) has a market capitalization of 3.88M USD. This makes HILS a Nano Cap stock.
When does HILLSTREAM BIOPHARMA INC (HILS) report earnings?
HILLSTREAM BIOPHARMA INC (HILS) will report earnings on 2023-11-06.